|
mind-body intervention |
12 |
|
cancer |
11 |
|
quality of life |
11 |
|
chinese |
10 |
|
cognitive behavioral therapy |
10 |
|
family caregiver |
10 |
|
lung cancer |
10 |
|
randomized controlled trial |
10 |
|
cognitive behavioural therapy |
9 |
|
family caregivers |
9 |
|
nasopharyngeal carcinoma |
9 |
|
non-small cell lung cancer |
9 |
|
plasma ebv dna |
9 |
|
recursive partitioning analysis |
9 |
|
stage classification |
9 |
|
survival prediction |
9 |
|
targeted therapy |
9 |
|
chemoradiotherapy |
8 |
|
neoadjuvant therapy |
8 |
|
oesophageal cancer |
8 |
|
oesophageal squamous cell carcinoma |
8 |
|
oesophagectomy |
8 |
|
chemotherapy |
7 |
|
comparative effectiveness |
6 |
|
family |
6 |
|
herbal medicine |
6 |
|
intervention research |
6 |
|
lungquality of life |
6 |
|
rct |
6 |
|
traditional chinese medicine |
6 |
|
aetiology |
5 |
|
gastric cancer |
5 |
|
immunotherapy |
5 |
|
metastatic |
5 |
|
palliative |
5 |
|
radiation therapy |
5 |
|
surgery |
5 |
|
systemic treatment |
5 |
|
cancer management |
4 |
|
chinese medicine |
4 |
|
esophageal squamous cell carcinoma |
4 |
|
immune checkpoint inhibitor |
4 |
|
target therapy |
4 |
|
aflibercept |
3 |
|
breast cancer |
3 |
|
chinese herbal medicine |
3 |
|
colorectal neoplasms |
3 |
|
hepatotoxicity |
3 |
|
liver toxicity |
3 |
|
meta-analysis |
3 |
|
nephrotic syndrome |
3 |
|
oncology |
3 |
|
proteinuria |
3 |
|
radiotherapy |
3 |
|
rucam |
3 |
|
side effect |
3 |
|
abiraterone (aa) |
2 |
|
acupuncture |
2 |
|
apalutamide |
2 |
|
artificial intelligence |
2 |
|
cancer incidence |
2 |
|
cancer mortality |
2 |
|
cancer patient |
2 |
|
cancer related symptoms |
2 |
|
cancer survival |
2 |
|
craniospinal irradiation |
2 |
|
docetaxel |
2 |
|
enzalutamide (enz) |
2 |
|
image acquisition |
2 |
|
image segmentation |
2 |
|
intensity-modulated |
2 |
|
lymphopenia |
2 |
|
medical physics |
2 |
|
palliative care |
2 |
|
pneumocystis jiroveci |
2 |
|
prostate cancer |
2 |
|
prostatic neoplasms |
1 |
|
therapeutics |
1 |
